Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KJ-C2527 (Kaixing Life Technology (Shanghai) Co., Ltd.)
- Development stage
- Preclinical
- Lead developer
- CARsgen Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KJ-C2527 is an investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy developed by Kaixing Life Technology, a subsidiary of CarsGen Therapeutics. It is designed to target Claudin18.2 (CLDN18.2), a tight junction protein that is frequently overexpressed in gastric and gastroesophageal junction cancers while maintaining restricted expression in normal tissues. As an allogeneic or "off-the-shelf" therapy, KJ-C2527 is derived from healthy donor T cells rather than the patient's own cells, which potentially allows for more rapid treatment delivery and reduced manufacturing costs compared to autologous CAR-T therapies. The therapy involves engineering these donor T cells to express a CAR specific to CLDN18.2, enabling them to recognize and eliminate tumor cells expressing the antigen. It is currently in preclinical development for the treatment of gastric cancer.
- Other names
- Claudin18.2-CAR-T cell therapy (allogeneic)
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on KJ-C2527 (Kaixing Life Technology (Shanghai) Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KJ-C2527 (Kaixing Life Technology (Shanghai) Co., Ltd.).